These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19267451)

  • 1. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.
    Chen Y; Sen J; Bathula SR; Yang Q; Fittipaldi R; Huang L
    Mol Pharm; 2009; 6(3):696-705. PubMed ID: 19267451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.
    Li SD; Huang L
    Biochim Biophys Acta; 2009 Oct; 1788(10):2259-66. PubMed ID: 19595666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
    Chen Y; Bathula SR; Li J; Huang L
    J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
    Chen Y; Wu JJ; Huang L
    Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.
    Li J; Chen YC; Tseng YC; Mozumdar S; Huang L
    J Control Release; 2010 Mar; 142(3):416-21. PubMed ID: 19919845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted delivery of siRNA by self-assembled nanoparticles.
    Li SD; Chen YC; Hackett MJ; Huang L
    Mol Ther; 2008 Jan; 16(1):163-9. PubMed ID: 17923843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface-modified LPD nanoparticles for tumor targeting.
    Li SD; Huang L
    Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted nanoparticles deliver siRNA to melanoma.
    Chen Y; Bathula SR; Yang Q; Huang L
    J Invest Dermatol; 2010 Dec; 130(12):2790-8. PubMed ID: 20686495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.
    Yang Y; Hu Y; Wang Y; Li J; Liu F; Huang L
    Mol Pharm; 2012 Aug; 9(8):2280-9. PubMed ID: 22686936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
    Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
    J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
    Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
    Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor.
    Li J; Yang Y; Huang L
    J Control Release; 2012 Feb; 158(1):108-14. PubMed ID: 22056915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
    Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
    Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
    Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.
    Chono S; Li SD; Conwell CC; Huang L
    J Control Release; 2008 Oct; 131(1):64-9. PubMed ID: 18674578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
    Yang Y; Li J; Liu F; Huang L
    Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle delivery of a peptide targeting EGFR signaling.
    Kim SK; Huang L
    J Control Release; 2012 Jan; 157(2):279-86. PubMed ID: 21871507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.